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Angiogenic Markers Show High Prognostic Impact on
Survival in Marginally Operable Non-small Cell Lung
Cancer Patients Treated with Adjuvant Radiotherapy
Sigve Andersen, MD,*† Tom Donnem, MD,*† Samer Al-Saad, MD,‡§ Khalid Al-Shibli, MD,‡
Lill-Tove Busund, MD, PhD,‡§ and Roy M. Bremnes, MD, PhD*†
Introduction: Protein expressions of angiogenic markers provide
prognostic information on patients with non-small cell lung cancer
(NSCLC). Both expression and its prognostic impact may be asso-
ciated with patient selection. Data addressing the prognostic rele-
vance of angiogenic marker expression in NSCLC patients treated
with postoperative radiotherapy (PORT) is warranted.
Methods: In 55 patients with stage I-IIIA NSCLC administered
PORT between 1990 and 2005, we have reviewed the clinicopath-
ological variables and investigated the expression of angiogenic
markers in tumor and stroma in tissue micro arrays.
Results: The median follow-up was 114 months and the major end
point disease-specific survival (DSS). Univariate analysis showed
that high expression of vascular endothelial growth factor A
(VEGF-A) (p  0.004), VEGF receptor-1 (VEGFR-1, p  0.028),
VEGFR-2 (p  0.021), VEGFR-3 (p  0.001) and platelet derived
growth factor (PDGF) in tumors correlated significantly with a poor
survival. Inversely, high basic fibroblast growth factor (bFGF)
expression in stroma was associated with significantly improved
DSS (p  0.017). In multivariate analyses, tumor PDGF expression
appeared independently associated with a shorter DSS (hazard ratio
5.42, p  0.002) and stromal bFGF expression an increased DSS
(hazard ratio 0.077, p  0.001).
Conclusions: Tumor PDGF expression was an independent nega-
tive prognostic factor and stromal bFGF expression an independent
positive prognostic factor for survival in NSCLC receiving PORT.
Key Words: NSCLC, Prognostic factors, Angiogenic markers,
Radiotherapy.
(J Thorac Oncol. 2009;4: 463–471)
Lung cancer is the leading cause of cancer-related deathsworld-wide and non-small cell lung cancer (NSCLC)
accounts for approximately 80% of all lung cancer cases.
Despite extensive efforts over the last decades, current treat-
ment modalities have only marginally improved survival
rates.1 Angiogenesis is considered a hallmark of cancer de-
velopment2 as tumor growth requires neovascularization to
grow beyond a diameter of 2 mm.3 Angiogenesis is facilitated
through secretion of ligands acting in an autocrine and paracrine
manner with binding to corresponding receptors.4 There is con-
siderable crosstalk between angiogenic pathways. These are
collectively involved in the onset of secretion and expression of
angiogenic factors, known as the angiogenic switch, which is
essential in tumor development and metastasis.5
The most important members of the vascular endothe-
lial growth factor (VEGF) family includes the ligands
VEGF-A, VEGF-C, VEGF-D, and the tyrosine kinase recep-
tors VEGFR-1, VEGFR-2, VEGFR-3. VEGF-A is considered
the dominant angiogenic factor promoting endothelial cell
proliferation, migration, vessel sprouting, remodeling, and
increased vascular permeability, by binding to the receptors
VEGFR-1 and VEGFR-2.6 VEGF-C and VEGF-D are thought
to be involved in lymphangiogenesis through binding to their
preferred receptor VEGFR-3.7
In the platelet derived growth factor (PDGF) family,
the following 5 isoforms have been identified: PDGF-AA,
PDGF-BB, PDGF-AB, PDGF-CC, PDGF-DD.8 These ligands
interact with the tyrosine kinase receptors PDGFR , 
(homodimers), and heterodimer  receptor with different
affinities.9,10 Physiologically, PDGF is a potent mitogen,
chemotactic factor for mesenchymal cells and it is involved in
angiogenesis. In tumor pathophysiology it is involved in
autocrine, stromal, and angiogenic stimulation.11,12
The fibroblast growth factor (FGF) family consists of
totally 22 structurally related members acting on tyrosine
kinase receptors (FGFRs). The most studied ligand is bFGF
(FGF2), and FGFR-1 and FGFR-2 are considered its recep-
tors. In angiogenesis, bFGF exerts its biologic activity by
binding to high affinity tyrosine kinase FGFRs, mainly
FGFR1. Activation of FGFR1 leads to endothelial cell pro-
liferation.13,14
Different angiogenic mechanisms may have diverse
potentials in different tumor types and at various stages of
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tumor progression. Tissue studies, as our tissue micro array
(TMA)-based IHC expression analyses, may provide critical
clinical information regarding tumor or stromal cell expres-
sion of candidate molecules for targeted antiangiogenic ther-
apy.15 Accordingly, we wanted to investigate the prognostic
impact of VEGF, PDGF and FGF ligands and their receptors
in a subgroup of NSCLC patients treated with postoperative
radiotherapy (PORT). This patient group is of particular
interest since PORT yields possible survival advantages for
patients with metastasis to the ipsilateral mediastinal and/or
subcarinal lymph nodes (N2-disease)16,17 and pathologically
positive margins after surgery.18,19
MATERIALS AND METHODS
Patients
Patients surgically resected for pathologically verified
NSCLC stage I-IIIA at the University Hospital of Northern
Norway and Nordland Central Hospital from 1990 and
through 2004, were retrospectively identified.
We identified 371 patients operated with curative intent
undergoing lobectomy or pneumonectomy. Of these, 63 pa-
tients had received radiotherapy within 12 weeks postopera-
tively, a cumulative biologic radiation dose of 50 Gy. No
adjuvant chemotherapy was administered. Three patients
were excluded due to other malignancy within 5 years before
NSCLC diagnosis, 3 due to preoperative chemotherapy and 2
because of inadequate paraffin-embedded surgical specimens,
leaving 55 patients to be included in this study.
Data on demographics and clinicopathological vari-
ables were collected retrospectively. Patients were staged
according to the International Union against Cancer’s tumor,
node, metastasis classification and histologically subtyped
and graded according to the World Health Organization
guidelines.20 This study has been approved by The National
Data Inspection Board and The Regional Committee for
Research Ethics.
Materials
The formalin-fixed and paraffin embedded surgical
specimens were obtained from the pathologic departments of
University Hospital of Northern Norway and Nordland Cen-
tral Hospital. All lung cancer cases were histologically re-
viewed and confirmed by two pathologists and the most
representative areas of neoplastic cells (denominated as tu-
mor) and tumor-related stroma (denominated stroma) were
carefully selected and marked on the hematoxylin and eosin
(H/E) slide.
Two core biopsies from tumor and two from stroma
were collected from each surgical specimen. All core biopsies
were inserted in a recipient block, constructing a total of eight
TMA blocks. The TMAs were assembled using a tissue-
arraying instrument (Beecher Instruments, Silver Springs,
MD). The detailed methodology has been previously report-
ed.21 Briefly, we used a 0.6 mm diameter stylet, and the study
specimens were routinely sampled with two replicate core
samples (different areas) of neoplastic tissue and two of
tumor stroma. Normal lung tissue, localized distant from the
primary tumor of the same patients, were used as negative
controls. All TMA slides also harbored positive controls.
Multiple 5-m sections were cut with a Micron microtome
(HM355S) and stained by specified antibodies for the immu-
nohistochemical (IHC) analyses.
Immunohistochemistry
All applied antibodies had been subjected to in-house
validation by the manufacturer for IHC analysis on paraffin-
embedded material. All sections were deparaffinised with
xylene and rehydrated with ethanol. The tissue cores were
subjected to rabbit polyclonal antibody VEGFR-1 (1:10,
RB-1527, Neomarkers Inc, CA), VEGFR-2 (1:25, RB-9239,
Neomarkers Inc, CA), VEGF-A (1:100, RB1678, Neomark-
ers Inc CA), PDGF (1:15, RB-9257, Neomarkers Inc CA),
VEGFR-3 antibody (1:100, Sc-321, Santa Cruz Biotechnol-
ogy, CA), VEGF-C antibody (1:25, 18–2255, Zymed labo-
ratories, CA), bFGF antibody (1:200, AB1458, Chemicon
international), FGFR1 antibody (1:50, SC-121, Santa Cruz
Biotechnology) and mouse monoclonal VEGF-D antibody
(1:40, MAB286, R&D Systems, MN).
Antigen retrieval was performed by placing the speci-
men in 0.01M citrate buffer at pH 6.0 and exposed to repeated
(2) microwave heating of 10 minutes at 450W. Exceptions
are bFGF and VEGFR-3 which were heated in a microwave
2 5 minutes at 250W, FGFR heated 2 minutes in a pressure
boiler and VEGF-D heated in a water incubator at 85°C for
45 minutes. The DAKO EnVision  System-HRP (DAB) kit
was used as endogen peroxidase blocking. For negative
staining controls, the primary antibodies were replaced with
the primary antibody diluent. Primary antibodies were incu-
bated for 30 minutes at room temperature. Exceptions were
VEGFR-3 which was incubated at 4°C for 20 minutes,
FGFR-1 for 1 hour in room temperature and VEGF-D over
night (approximately 17 hours) at 4°C. The kit DAKO En-
Vision System-HRP (DAB) included secondary antibodies
and these were applied for 30 minutes at room temperature.
Subsequently, liquid diaminobenzidine and substrate-chro-
mogen were added, yielding a brownish reaction product at
the site of the target antigen. Finally, all slides were counter-
stained with hematoxylin to visualize the nuclei. For each
antibody, including negative staining controls, TMA staining
was performed in one single procedure.
Scoring of Immunohistochemistry
The TMA core biopsies were scored semiquantitatively
for IHC staining, by light microscopy. The staining intensity
in both tumor cores and stroma cores was scored as: 0 
negative; 1  weak; 2  intermediate; 3  strong. The
staining density in stroma cores was scored as; 1  weak;
2  intermediate; 3  strong. The TMA cores were scored
anonymously and independently by two pathologists. In case
of disagreement, the slides were reexamined and a consensus
was reached by the observers. When assessing one variable
for a given core, the observers were blinded to the scores of
the other variables and to outcome. To evaluate the interin-
dividual variability with respect to IHC scoring, 100 consec-
utive tumor cell cores and stroma cores stained for VEGF-C
and VEGFR-3, evaluated by our two pathologists.22
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Mean score for the duplicate cores for each surgical
specimen was calculated separately for tumor tissue and
stroma. High expression in tumor was defined as score  3
(VEGF-A, PDGF, bFGF) or 2.5 (VEGF-C, VEGF-D,
VEGFR-1, VEGFR-2, VEGFR-3, FGFR). Stromal expres-
sion was calculated by summation of density score (1–3) and
intensity score. (0–3) High expression in stroma was defined
as score 4 (except bFGF 4.5). Examples of staining
intensities for bFGF in stroma and PDGF in tumor are shown
in Figure 1.
In stead of using the overall mean score as cutoff value,
the cutoffs were chosen at levels securing statistically suffi-
cient numbers in each group and appearing most biologically
plausible. Hence, in this study the cutoff values varied among
the angiogenic markers. As a consequence, the results need to
be interpreted with caution, especially at weak significance
levels, as the risk of type I error (false positive results)
increases. However, the use of mean staining score may have
led to clinically important findings remaining undetected as
the staining intensity varied greatly between different IHC
antibodies.
Statistical Methods
The SPSS version 14.0.1 from SPSS Inc, Chicago was
used for the statistical analyses. The 2 test and Fisher’s exact
test were used to examine the association between molecular
marker expression and various clinicopathological parame-
ters. Kaplan-Meier method was used for univariate testing
and statistical significance between survival curves was as-
sessed by the log-rank test. Variables of significant value
from the univariate analysis were entered into multivariate
analysis using backward stepwise Cox regression analysis. A
p  0.05 was considered statistically significant.
RESULTS
Patient Characteristics
At the last follow-up in September 2005, the disease
specific survival (DSS) was determined from the date of
surgery to the time of lung cancer death. The median fol-
low-up was 114 months (range 10–188 months), and the
median survival for all 55 patients was 42 months (range
3–141). The 5-year DSS was 47% and 10-year DSS was 43%.
In univariate analyses (Table 1), weight loss 10% (p 
0.036), poor tumor cell differentiation (p  0.05), and nodal
metastasis (p  0.014) were prognostic variables.
Immunohistochemical Scoring and
Interobserver Variability
The interobserver scoring agreement was tested for one
ligand (VEGF-C) and one receptor (VEGFR-3). The IHC
scores from each observer were compared for interobserver
reliability by use of a two-way random effect model with
absolute agreement definition. The intraclass correlation co-
efficient (reliability coefficient, r) was obtained from these
results.
VEGF-C: tumor r  0.95, p  0.001; stroma intensity
r  0.93, p  0.001; stroma density r  0.93, p  0.001.
VEGFR-3: tumor r  0.98, p  0.001; stroma intensity r 
0.96, p  0.001; stroma density r  0.97, p  0.001.
Expression Patterns in Tumor and Stroma
All categories of expression (negative-weak, interme-
diate, and high) were present in the tumor core assessments.
All stromal cores showed some expression of the various
angiogenic markers. The expression of the ligands was pri-
marily cytoplasmic, but expression of the receptors was both
cytoplasmic and membranous. The expression of the specific
antibodies is shown in Table 2.
Association Between Molecular Marker
Expression and Disease-Free Survival
Data are presented in Table 3. Univariate analyses
showed that high tumor cell expression of the ligand
VEGF-A (p  0.004) and the receptors VEGFR-1 (p 
0.028), VEGFR-2 (p  0.021) and VEGFR-3 (p  0.001),
correlated significantly with a poor survival (Figure 2).
High PDGF expression was also associated with a poor
survival (p  0.002, Figure 3). However, the tumor cell
expression of the ligands VEGF-C, VEGF-D and bFGF
and the receptor FGFR, was not significantly associated
with survival in this study.
In stroma, only bFGF expression (p  0.017, Figure
4) exhibited a significant association with survival. In
contrast to our findings in tumors, a high stromal bFGF
expression correlated to an improved patient survival.
Stromal VEGF-C expression showed a similar trend, but
did not reach statistical significance (p  0.066).
FIGURE 1. Immunohistochemical analysis of tissue micro
array (TMA) of non-small cell lung cancer (NSCLC) repre-
senting different score for tumor cell platelet-derived growth
factor (PDGF) and stromal basic fibroblast growth factor
(b-FGF); (A) Tumor cell PDGF score 0; (B) Tumor cell PDGF
score 3; (C) Stromal b-FGF low score (density 1, intensity 1);
(D) Stromal b-FGF high score (density 3, intensity 3).
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TABLE 1. Prognostic Clinicopathologic Variables as Predictors of Disease Specific Survival in
55 NSCLC-Patients Receiving Adjuvant Postoperative Radiotherapy
Characteristics Patients (n) Patients (%)
Median
Survival (mo)
5-yr
Survival (%) p
Age 0.668
65 yr 31 56 46 49
65 yr 24 44 41 45
Sex 0.298
Female 17 31 64 61
Male 38 69 26 41
Smoking status 0.664
Never 1 2 NR 100
Previous 23 42 47 43
Present 31 56 41 48
WHO performance status 0.146
0 28 51 NR 53
1 23 42 21 37
2 4 7 NR 67
Weight loss 0.036
10% 49 89 47 50
10% 6 11 8 17
Histology 0.158
Squamous cell carcinoma 33 60 128 60
Adenocarcinoma 16 29 21 35
Large cell carcinoma 6 11 18 17
Differentiation 0.05
Poor 27 49 18 27
Moderate 21 38 127 69
Well 7 13 NR 63
Surgical procedure 0.463
Lobectomy 29 53 47 49
Pneumectomy 26 47 18 43
Stage 0.074
I 9 16 64 73
II 23 42 NR 57
IIIA 23 42 19 28
Tumor status 0.225
1 7 13 127 53
2 40 73 24 42
3 8 14 NR 69
Nodal status 0.014
0 14 26 NR 83
1 19 34 41 49
2 22 40 19 24
Surgical margins 0.109
Free 37 67 21 63
Not free 18 33 64 67
Clinician reason for PORT
Insufficient margin or tumor cells
in resection margin
18 33 NR 70 0.092
N1 14 26 16 50
N2 20 36 19 25
Early local recurrence 3 5 NR 67
Fractioning regime 0.597
2,8  15  42 Gy 29 53 19 45
2  30  60 Gy 21 38 47 46
2  25–29  50–58 Gy 5 9 24 40
WHO, World Health Organization; PORT, postoperative radiotherapy; NCSLC, non-small cell lung cancer; NR, not reached.
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Multivariate Analysis
When all clinical and molecular variables with a sig-
nificant impact on survival in the univariate analyses were
entered into the Cox multivariate model, weight loss (p 
0.018), nodal status (p  0.001), tumor PDGF expression
(p  0.002), and stromal bFGF expression (p  0.0001),
were independently associated with DSS (Table 4).
Comparison Between PORT-Treated Patients
and Nonirradiated Stage II and IIIA Patients
The 74 stage II-IIIA patients (69 stage II, 5 stage IIIA)
in the study by Donnem et al.,22 who did not receive radio-
therapy, were selected as an unmatched control group. Due to
significant differences with respect to prognostic markers for
survival, matching with the PORT group was not possible.
The purpose with this unmatched control group was to
compare the results from the 55 PORT patients with closely
resembling patients not receiving radiotherapy.
In these 74 patients, only pathologic stage (IIIA versus
stage II, p  0.001) was a statistically significant prognostic
variable for DSS (univariate analyses) among the clinicopath-
ological variables. Median survival was 36 months (range
3–160 months), and the DSS was similar between PORT
patients and this control group (p  0.54).
Univariate analyses showed only tumor cell VEGF-C
expression (p  0.026) to correlate significantly with a poor
survival in the control group, while tumoral PDGF, VEGF-A,
VEGFR-1, VEGFR-2, and VEGFR-3 were significantly cor-
related with a poor survival in the PORT group. Among the
unmatched controls the only marker independently associated
with DSS was tumoral VEGF-C (p  0.039). These findings
contrasted our results in the PORT treated group where
tumoral PDGF and stromal bFGF were independently asso-
ciated with DSS.
DISCUSSION
In our study cohort of 55 PORT treated stage I-IIIA
NSCLC patients, PDGF expression in tumor emerged as an
independent poor prognosticator DSS, whereas bFGF expres-
sion in stroma was a beneficial prognostic marker.
The prognostic impact of VEGF markers in NSCLC
tumors has previously been published by several investiga-
tors.22–26 Besides the report by Guddo et al.,27 that stromal
bFGF expression correlated with nodal metastasis, there are
no previous reports on stromal bFGF and survival. Regarding
tumor cell PDGF/PDGFR expression in NSCLC, there are, to
our knowledge, only two previous studies. PDGF-AA was by
Shikada et al.26 reported to have a negative prognostic impact
in univariate analysis. Kawai et al.28found PDGF-B expres-
sion, by IHC, to predict a negative outcome in 92 resected
patients. The strengths of our study are the examination of
both the stromal and tumor cell expression. In our subgroup
of operable unselected NSCLC patients who received adju-
vant PORT due to N2 disease or positive surgical margins,
we demonstrate the strong prognostic impact of tumor cell
PDGF expression and stromal bFGF expression, even in
multivariate analyses. As several ongoing phase I and II studies
are investigating different targeted therapies in NSCLC, e.g.,
TABLE 2. Expression of Molecular Markers in Surgical
Specimens from Patients
Molecular Marker
Tumor Cores Stromal Cores
Score
Patients
Scorea
Patients
n % n %
VEGF-A
Mean score 0–1 4 7 1–2 0 0
1.5–2 22 40 2.5–3.5 43 78
2.5–3 29 53 4–6 12 22
Median 2.5 3.5
Range 0.5–3.0 2.5–5
VEGF-C
Mean score 0–1 25 46 1–2 3 5
1.5–2 20 36 2.5–3.5 43 78
2.5–3 10 18 4–6 9 16
Median 1.5 3
Range 0.5–3 1.5–4.5
VEGF-D
Mean score 0–1 6 11 1–2 0 0
1.5–2 22 40 2.5–3.5 43 78
2.5–3 27 49 4–6 12 22
Median 2 3
Range 1–3 2.5–4.5
VEGFR1
Mean score 0–1 13 23 1–2 12 22
1.5–2 21 38 2.5–3.5 20 36
2.5–3 21 38 4–6 23 42
Median 2 3.5
Range 0–3 1–5
VEGFR2
Mean score 0–1 11 20 1–2 6 11
1.5–2 24 44 2.5–3.5 41 75
2.5–3 20 36 4–6 8 14
Median 2 3
Range 0–3 1–5
VEGFR3
Mean score 0–1 6 11 1–2 0 0
1.5–2 19 34 2.5–3.5 39 71
2.5–3 30 55 4–6 16 29
Median 2.5 3.5
Range 1–3 2.5–5
PDGF
Mean score 0–1 2 4 1–2 0 0
1.5–2 24 43 2.5–3.5 41 75
2.5–3 29 53 4–6 14 25
Median 2.5 3.5
Range 1–3 2.5–5
bFGF
Mean score 0–1 6 11 1–2 0 0
1.5–2 32 58 2.5–3.5 27 49
2.5–3 17 31 4–6 28 51
Median 2 3
Range 1–3 2.5–5.5
FGFR
Mean score 0–1 17 31 1–2 1 2
1.5–2 24 44 2.5–3.5 39 71
2.5–3 14 25 4–6 14 25
Missing Missing 1 2
Median 2 3
Range 1–3 2–5
a Mean score of density plus intensity.
VEGF, vascular endothelial growth factor; PDGF, platelet derived growth factor;
bFGF, basic fibroblast growth factor; FGFR, fibroblast growth factor receptors.
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TABLE 3. Prognostic Molecular Variables in Tumor and Stroma as Predictors of Disease
Specific Survival in 55 NSCLC-Patients Receiving Adjuvant Postoperative Radiotherapy
Molecular
Marker
Compartment and
Expression Patients n (%)
Median
Survival (mo)
5-yr
Survival (%) p
VEGF-A Tumor 0.004
High 16 (29) 13 20
Low 39 (71) 127 59
Stroma 0.913
High 12 (22) 41 40
Low 43 (78) 47 49
VEGF-C Tumor 0.595
High 10 (18) 24 40
Low 45 (82) 47 49
Stroma 0.066
High 9 (16) NR 42
Low 46 (84) 28 64
VEGF-D Tumor 0.370
High 27 (49) 24 42
Low 28 (51) 127 51
Stroma 0.725
High 12 (22) 40 44
Low 43 (78) 47 48
VEGFR-1 Tumor 0.028
High 21 (38) 18 31
Low 34 (62) 127 55
Stroma 0.983
High 23 (42) 40 49
Low 32 (58) 46 45
VEGFR-2 Tumor 0.021
High 20 (36) 15 26
Low 35 (64) 127 59
Stroma 0.518
High 8 (14) 20 50
Low 47 (86) 40 46
VEGFR-3 Tumor 0.001
High 30 (54) 18 27
Low 25 (46) NR 69
Stroma 0.547
High 16 (29) 127 53
Low 39 (71) 41 44
PDGF Tumor 0.002
High 12 (22) 12 25
Low 43 (78) 127 54
Stroma 0.245
High 14 (26) 127 59
Low 41 (74) 24 43
bFGF Tumor 0.752
High 17 (31) 26 47
Low 38 (69) 47 47
Stroma 0.017
High 11 (20) NR 81
Low 44 (80) 24 37
FGFR Tumor 0.977
High 14 (25) 47 44
Low 41 (75) 41 48
Stroma 0.426
High 14 (25) 127 54
Low 40 (73) 47 47
Missing 1 (2)
In tumor, high expression was defined as score  3 (VEGF-A, PDGF, bFGF) or 2.5 (VEGF-C, VEGF-D, VEGFR-1,
VEGFR-2, VEGFR-3, FGFR).
In stroma, expression was calculated by summarizing density score (1–3) and intensity score (0–3). High expression in
stroma was defined as score 4 (except bFGF 4.5).
NR, not reached; NCSLC, non-small cell lung cancer; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast
growth factor; PDGF, platelet derived growth factor; FGFR, fibroblast growth factor receptors.
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against VEGF-A (bevacizumab), PDGFR (imatinib) and EGFR
(erlotinib, gefitinib, and cetuximab) (www. clinicaltrials.gov),
there is still limited knowledge on the relevance of these markers
in marginally operable NSCLC patients.
In this study, we observed a greater prognostic impact
of the majority of these molecules in our study cohort, when
compared with the above mentioned studies.22–25,27 In the
study by Donnem et al.,22 a high tumor VEGF-A expression
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FIGURE 2. Disease specific survival curves according to (A), tumor cell expression of VEGF-A; (B), tumor cell expression of
VEGFR-1; (C), tumor cell expression of VEGFR-2 and (D), tumor cell expression of VEGFR-3.
FIGURE 3. Disease specific survival curve according to tu-
mor cell expression of PDGF.
FIGURE 4. Disease specific survival curve according to stro-
mal expression of bFGF.
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led to a 48% 5-year DSS whereas low expression yielded
66%, leaving a DSS difference of 18%. In comparison, our
study shows a 39% difference in 5-year DSS for high versus
low tumor expression of VEGF-A. In fact, this was also seen
for VEGFR-1, VEGFR-2, and VEGFR-3. Furthermore, we
also observed a substantial difference in hazard ratios
between patients with high versus low expression of PDGF
and bFGF.
VEGFR-3 is considered important primarily for lym-
phangiogenesis7. Consequently, a high tumor expression of
VEGFR-3 might be associated to lymph node metastasis. In
the multivariate analysis, however, nodal status, but not
VEGFR-3, appeared as an independent prognosticator for
survival, although the latter was highly associated with DSS
in the univariate analysis. In circumstances where two prog-
nostically significant variables covariate, only the strongest
variable will appear independent in the multivariate analysis.
This fact, however, can not rule out the prognostic impact of
VEGFR-3.
Our results could be incidental, but the differences in
DSS are highly prominent for most of the prognostic markers,
suggesting validity of our results. The way we chose our
cutoff values may possibly increase the risk of false positive
results. However, as our results were highly significant, the
risk of type I errors seems unlikely. One may speculate
whether the expression of VEGF-A, VEGFR-1, VEGFR-2,
VEGFR-3, and PDGF in tumor and bFGF in stroma may to
some degree be predictive for the outcome of radiotherapy.
This may be supported by the substantial difference in DSS
between patients expressing these markers at high versus low
level in our subgroup. Moreover, while the prognostic value
of tumor PDGF and stromal bFGF expression was highly and
independently significant in our PORT group, these markers
had no prognostic impact in our unmatched control group
(nonirradiated stage II and IIIA patients). Consequently,
though this was not a matched control group, one may
question, whether the expression of PDGF, bFGF, and other
angiogenic markers may predict irradiation efficacy in lung
cancer patients. To further address this hypothesis, a future
prospective trial will need to assess the predictive value of
these markers in NSCLC patients receiving thoracic radio-
therapy.
As suggested by Duda et al.,15 tissue studies may
provide critical information regarding tumor or stromal cell
expression of the molecule targeted by a specific antiangio-
genic agent. This study yields interesting data indicating that
antiangiogenic molecules may possibly potentiate the effect
of PORT to marginally operable NSCLC patients.
The biologic mechanism behind our results may possi-
bly be explained by these markers’ roles in tumor physiology.
Earlier reports have demonstrated that high VEGFR signaling
and receptors activated by PDGF-B (phosphorlylated
PDGFR-beta) are involved in an interstitial fluid pressure
(IFP) increase in solid tumors.29 Besides, an elevated IFP
correlate with tumor hypoxia.30,31 Through imatinib-induced
inhibition of PDGFR-beta in NSCLC adenocarcinoma-bear-
ing mice it has been possible to improve oxygenation.32
Moreover, elevated IFP and tumor hypoxia have been recog-
nized as independent predictors for a poorer radiation re-
sponse in cervical carcinoma33–35 and head and neck can-
cers36–38 thereby affecting both survival and local control. The
question is whether overexpression of VEGF-A, VEGFR-1,
VEGFR-2, VEGFR-3 and PDGF-B in the NSCLC tumors
investigated herein may predict reduced radiosensitivity,
given the large DSS difference between irradiated patients
with high versus low marker expressions.
If so, expression of these markers in NSCLC-tumors
and stroma might become potential targets for radiotherapy
treated NSCLC patients. In preclinical studies on tumor
xenografts of various origins, it has previously been shown
that antiangiogenic therapy may increase the efficacy of
radiotherapy in an additive or even synergistic way.39–44
An argument against these hypothesized mechanisms is
that PORT for NSCLC improves survival only marginally
even for selected patients with N2-disease and pathologic
surgical margins.16–19 Further, the good prognostic impact of
high bFGF expression in stroma can not be explained by the
proposed hypothesis.
Another possible explanation is that residual disease
and relapse are more frequent in these marginally operable
patients versus earlier stage disease. Thus angiogenesis may
have a considerable stronger prognostic impact in these
NSCLC patients treated with PORT. If so, antiangiogenic
therapy should be considered evaluated as an adjuvant ther-
apy to these patients in the postoperative phase.
As the number of patients included in this study is
relatively low, the data should be interpreted with caution and
confirmed through larger future studies. Molecular biologic
findings such as increased gene expression or promoter ac-
tivity, would provide further evidence. Several other mole-
cules including PDGF receptors and their ligands would also
be of interest. Future research should address these topics and
penetrate the biologic basis for angiogenic marker induced
radiosensitivity, thereby hopefully facilitating future clinical
radiotherapy studies on supplementary molecular therapy.
TABLE 4. Hazard Ratios of Significant Variables in
Multivariate Analysis
Variable
Hazard
Ratio
95% Confidence
Intervals p
Weight loss 0.018
10% 1
10% 7.07 (1.4–35.6)
Nodal status 0.001
0 1
1 6.22 (1.27–30.6)
2 9.56 (2.34–39.1)
Tumor PDGF 0.002
Low 1
High 5.42 (1.93–15.2)
Stroma bFGF 0 .0001
Low 1
High 0.077 (0.015–0.40)
bFGF, basic fibroblast growth factor; PDGF, platelet derived growth factor.
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